EU MDR Article 56: Technical Documentation Assessment for High-Risk Devices

1. Key takeaways

Under Article 56 of the MDR, for Class III devices and for Class IIb implantable devices other than sutures, staples, dental fillings, dental braces, dental crowns, screws, wedges, bone plates, wires for fixation, pins, clips and connectors, the notified body must perform an assessment of the technical documentation. The exemption list is governed by delegated acts, and the most recent revision is Delegated Regulation (EU) 2026/1359, dated 2026-03-20.

The scope of this obligation deserves close reading, because it determines both the cost structure and the timeline of the certification project. The assessment requirement operates on top of the normal Annex IX procedure and does not replace the quality management system audit or the sampled documentation review; it adds a further, deeper look at the documentation of the devices concerned. Whether a given Class IIb implantable device falls inside or outside the obligation depends on the exemption list, which is not a static text: it is maintained through delegated acts and was revised again in 2026. Project budgets, timelines and documentation strategies should therefore be set only after the current list has been checked, and the determination should be recorded in the project file with the version of the list that was used.

2. Legal basis

Article 56 sits within Regulation (EU) 2017/745, adopted on 2017-04-05 and applicable since 2021-05-26, and interacts with the technical documentation assessment in Annex IX Chapter II. The delegated act of 2026-03-20 updates the exemption list, and the 2026 implementing act harmonises the operational requirements for the assessment process itself. All three layers must be read together: the article sets the obligation, the delegated act sets its boundaries, and the implementing act sets how notified bodies operate when performing it.

3. Expert insights

Insight one: the per-device assessment targets each individual device, not each model or device group.

The assessment under Article 56 targets the devices concerned themselves, rather than being sampled by device group. This makes the assessment workload and cost for Class III devices and for the affected Class IIb implantables significantly higher than for the regular sampled review. When compiling the technical documentation, manufacturers must therefore organise the evidence chain at a granularity that can withstand a device-by-device examination, rather than assuming that group-level reasoning will cover every variant. Documentation that passes a sampled review can still fail a per-device assessment if individual configurations lack their own traceable evidence.

Insight two: the exemption list is dynamic and was revised again in 2026.

Delegated Regulation (EU) 2026/1359, dated 2026-03-20, revised the list of Class IIb implantable devices exempt from this assessment obligation. Delegated acts belong to the detail level of the framework and are revised more frequently than the regulation itself. Before scheduling a project, the current version of the list must be checked, and the exemption status of the product must not be judged from an older version. Because the list directly switches an expensive obligation on or off, changes to it are commercially significant: an exemption granted in a revision can reduce scope and cost, while a removal from the list can invalidate an existing project plan. Monitoring the delegated acts is part of ongoing portfolio compliance management, not a one-time research task.

Insight three: the requirement imposed on the technical documentation is that evidence can be located directly.

A per-device assessment means the reviewer traces every chain: design requirement, risk analysis, verification report, clinical evidence, labelling and instructions for use. The retrievability of the technical documentation, which Annex II requires to be clear, organised, readily searchable and unambiguous, becomes a substantive issue at this point rather than a matter of presentation. A document set with excellent content but weak indexing will consume review cycles and generate clarification rounds, because the reviewer cannot connect claims to evidence efficiently. Manufacturers facing a per-device assessment should invest in the navigation layer of their documentation, including indices that link each general safety and performance requirement to the specific files that evidence it.

Insight four: this mechanism and the Article 54 expert panel procedure are two independent high-risk mechanisms.

Article 56 resolves who assesses the technical documentation, while the clinical evaluation consultation procedure (CECP) under Article 54 brings the expert panel opinion on clinical evidence. The two can apply simultaneously to the same device and cannot replace each other. Planning documents that assume the completion of one mechanism discharges the other create real schedule risk, because both consume notified body and expert panel capacity on independent timelines. Where a device is subject to both, the project plan should treat them as parallel workstreams with their own dependencies, inputs and review rounds, rather than as sequential stages of a single review.

4. Practical recommendations

1. When determining whether the product falls within the scope of Article 56, check both the body of the regulation and the exemption list of (EU) 2026/1359, and record the versions used in the determination.
2. Organise the technical documentation to be traceable item by item, and build an index table linking each GSPR clause to the numbering of the evidence files that support it.
3. Prepare the clinical evaluation report and the PMCF plan in advance, and submit them in synchronisation with the Article 56 assessment.
4. For implantable products, prepare the draft summary of safety and clinical performance (SSCP) under Article 32 at the same time, so that the publication obligation does not become a separate late project.
5. Build the project budget on the basis of a per-device assessment rather than a sampled assessment, since the review depth and the number of clarification rounds differ materially.

5. Verification checklist

• □ Whether the product falls within the scope of Article 56 has been determined
• □ The exemption list of (EU) 2026/1359 (2026-03-20) has been checked
• □ The technical documentation has an index table linking GSPR clauses to evidence
• □ The clinical evaluation report and the PMCF plan have been prepared in parallel
• □ The SSCP draft has been prepared, where applicable
• □ The budget has been built on the per-device assessment basis

GRZAN supports manufacturers, authorised representatives and importers across the EU MDR market with CE marking pathway selection and classification strategy, including Article 56 scope determinations, exemption list monitoring under the delegated acts, and technical documentation structuring for per-device assessments. For a practical estimate of assessment timelines and documentation effort for your portfolio, contact GRZAN at info@grzanglobal.com.

Regulatory information verified as of 2026-10-29.